CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
5 ways electronic health records are boosting patient outcomesThanks to the backing of governments and policymakers the world over, electronic health records have become more prevalent Share X5 ways electronic health records are boosting patient outcomeshttps://pharmaphorum.com/views-analysis-digital/5-ways-electronic-health-records-are-boosting-patient-outcomes/
The future of real world evidenceIncreasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role Share XThe future of real world evidencehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/
Making real world evidence fit for purposeAlthough real world evidence (RWE) is a hot topic in pharma right now, many still question whether it Share XMaking real world evidence fit for purposehttps://pharmaphorum.com/views-analysis-market-access/making-real-world-evidence-fit-for-purpose/
AI-powered study backs anticoagulants for heart failure patients without AFA new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of Share XAI-powered study backs anticoagulants for heart failure patients without AFhttps://pharmaphorum.com/news/ai-powered-study-backs-anticoagulants-for-heart-failure-patients-without-af/
Real-world data backs Kymriah’s safety profile, says NovartisWith more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the Share XReal-world data backs Kymriah’s safety profile, says Novartishttps://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/
Real-world or real evidence?There was a time when the distinction between data from clinical trials and data from any other source Share XReal-world or real evidence?https://pharmaphorum.com/r-d/views-analysis-r-d/real-world-or-real-evidence/
Nine for 2019: Opportunities for pharmaIn the last Nine for 2019 article, we reflected on the major challenges that are shaping the pharmaceutical Share XNine for 2019: Opportunities for pharmahttps://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/
Boosting clinical trial productivity to prove Eroom wrongAccording to Eroom’s law, drug discovery becomes slower and costlier over time. And the data are, at least Share XBoosting clinical trial productivity to prove Eroom wronghttps://pharmaphorum.com/r-d/boosting-clinical-trial-productivity-to-prove-eroom-wrong/
